A report from The Irish Times on November 12, 2025, revealed that Eli Lilly's blockbuster weight-loss drugs, Mounjaro and Zepbound, are the primary drivers behind Ireland's projected 11% GDP growth for the year. The surge is attributed to the manufacture of the drugs' active ingredients at Lilly's facility in Kinsale, Co Cork, which has caused an unprecedented spike in the nation's exports. This growth positions Ireland as the fastest-growing economy in the world for 2025, almost entirely due to the performance of these two products from a single company. The analysis also highlighted the significant concentration risk this creates for the Irish economy, which is now exceptionally dependent on the continued global demand for Lilly's treatments.